CN110114074B - 用于治疗或预防出血的凝血因子替代产品 - Google Patents

用于治疗或预防出血的凝血因子替代产品 Download PDF

Info

Publication number
CN110114074B
CN110114074B CN201880005539.2A CN201880005539A CN110114074B CN 110114074 B CN110114074 B CN 110114074B CN 201880005539 A CN201880005539 A CN 201880005539A CN 110114074 B CN110114074 B CN 110114074B
Authority
CN
China
Prior art keywords
factor
treatment
product
atiii
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880005539.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110114074A (zh
Inventor
E·赫佐格
G·霍赫莱特纳
O·格罗特克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of CN110114074A publication Critical patent/CN110114074A/zh
Application granted granted Critical
Publication of CN110114074B publication Critical patent/CN110114074B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880005539.2A 2017-02-09 2018-02-09 用于治疗或预防出血的凝血因子替代产品 Active CN110114074B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17155420 2017-02-09
EP17155420.7 2017-02-09
PCT/EP2018/053240 WO2018146235A1 (en) 2017-02-09 2018-02-09 A blood coagulation factor replacement product for use in the treatment or prophyl of bleedings

Publications (2)

Publication Number Publication Date
CN110114074A CN110114074A (zh) 2019-08-09
CN110114074B true CN110114074B (zh) 2024-05-28

Family

ID=58016586

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880005539.2A Active CN110114074B (zh) 2017-02-09 2018-02-09 用于治疗或预防出血的凝血因子替代产品

Country Status (13)

Country Link
US (1) US11744880B2 (https=)
EP (1) EP3579857B1 (https=)
JP (1) JP7227905B2 (https=)
KR (1) KR102658958B1 (https=)
CN (1) CN110114074B (https=)
AU (1) AU2018217375B2 (https=)
BR (1) BR112019012772A2 (https=)
CA (1) CA3046406C (https=)
DK (1) DK3579857T3 (https=)
ES (1) ES2913934T3 (https=)
PL (1) PL3579857T3 (https=)
SG (1) SG10201912497WA (https=)
WO (1) WO2018146235A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021201950A1 (en) * 2020-04-04 2021-10-07 The Board Of Regents Of The University Of Texas System Method for reducing the occurrence of thrombosis or thromboembolism
CN113929741A (zh) * 2020-06-29 2022-01-14 首都医科大学 华法林-4-O-乙酰-Gly-Pro-Arg-Pro-AA1及其合成、活性和应用
WO2026048976A1 (ja) * 2024-08-30 2026-03-05 Ｋｍバイオロジクス株式会社 血液凝固第ｘ因子を含む安定な医薬組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663164A (en) * 1980-01-28 1987-05-05 Baxter Travenol Laboratories, Inc. Aqueous compositions for treating blood clotting factor inhibitors
US5866122A (en) * 1996-03-20 1999-02-02 Immuno Aktiengesellschaft Pharmaceutical preparation for treating blood coagulation disorders
US6346277B1 (en) * 1983-10-08 2002-02-12 Aventis Behring Gmbh Process for the pasteurization of plasma or concentrates of blood coagulation factors II, VII, IX and X
CN102459583A (zh) * 2009-06-05 2012-05-16 法国分馏学和生物学实验室 凝血酶原复合体组合物
WO2016198351A1 (en) * 2015-06-10 2016-12-15 Evonik Röhm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3101752A1 (de) 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
AT409334B (de) * 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
WO2004068109A2 (en) * 2003-01-27 2004-08-12 Harvest Technologies Inc Autologous or homologous coagulant produced from anticoagulated whole blood
CA2812888A1 (en) 2010-10-06 2012-04-12 Medimmune Limited Factor ii and fibrinogen for treatment of haemostatic disorders
TWI653047B (zh) 2014-03-14 2019-03-11 百特製藥公司 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663164A (en) * 1980-01-28 1987-05-05 Baxter Travenol Laboratories, Inc. Aqueous compositions for treating blood clotting factor inhibitors
US6346277B1 (en) * 1983-10-08 2002-02-12 Aventis Behring Gmbh Process for the pasteurization of plasma or concentrates of blood coagulation factors II, VII, IX and X
US5866122A (en) * 1996-03-20 1999-02-02 Immuno Aktiengesellschaft Pharmaceutical preparation for treating blood coagulation disorders
CN102459583A (zh) * 2009-06-05 2012-05-16 法国分馏学和生物学实验室 凝血酶原复合体组合物
WO2016198351A1 (en) * 2015-06-10 2016-12-15 Evonik Röhm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
PCC中不同水平抗凝血酶和肝素对其促凝及抗凝能力的影响;辛叶等;《中国生化药物杂志》;20150428(第04期);全文 *
人凝血酶原复合物的研究进展;文圆等;《微生物学免疫学进展》;20120820(第04期);全文 *
刘新民.中华医学百科大辞海 第1卷 内科学.军事医学科学出版社,2008,第962页. *
曾戎 等.白蛋白.《生物医用仿生高分子材料》.华南理工大学出版社,2010,第115页. *
杨玉 等.新药临床应用指南.东南大学出版社,1997,第590页. *
魏旭东等.ATⅢ浓缩物.《血液病药物手册》.人民卫生出版社,2001, *

Also Published As

Publication number Publication date
JP7227905B2 (ja) 2023-02-22
ES2913934T3 (es) 2022-06-06
EP3579857B1 (en) 2022-04-06
CA3046406C (en) 2024-01-30
AU2018217375B2 (en) 2024-04-18
AU2018217375A1 (en) 2019-06-27
WO2018146235A8 (en) 2019-05-09
BR112019012772A2 (pt) 2019-12-10
US11744880B2 (en) 2023-09-05
DK3579857T3 (da) 2022-06-07
CN110114074A (zh) 2019-08-09
JP2020506880A (ja) 2020-03-05
KR102658958B1 (ko) 2024-04-22
EP3579857A1 (en) 2019-12-18
PL3579857T3 (pl) 2022-07-25
KR20190111912A (ko) 2019-10-02
SG10201912497WA (en) 2020-02-27
CA3046406A1 (en) 2018-08-16
WO2018146235A1 (en) 2018-08-16
US20190351028A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
RU2292909C2 (ru) Комбинированное применение полипептидов фактора vii и полипептидов фактора ix
Smith et al. Polyphosphate as a general procoagulant agent
EP0082182B1 (en) Composition based on the hemostatic agent factor viia and method of preparing same
KR101567762B1 (ko) Ｆｖⅲ 농축물을 포함하는 프로트롬빈 복합체 농축물의 상승적 치료 용도
US7425539B2 (en) Factor IXa for the treatment of bleeding disorders
US9968662B2 (en) Factor VII composition
JP2003532684A (ja) 第ＶＩＩａ因子及びＴＦＰＩ阻害剤を含んで成る医薬組成物
JPH1045620A (ja) 血液凝固疾患処置用医薬製剤
JP2005510515A (ja) Ｖｉｉ因子ポリペプチドおよびプロテインｃ阻害剤を含む薬学的組成物
CN110114074B (zh) 用于治疗或预防出血的凝血因子替代产品
JP6000259B2 (ja) 止血障害治療用第ｉｉ因子およびフィブリノーゲン
HK40017756A (en) A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
HK40017756B (en) A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
JP2005511599A (ja) Ｖｉｉ因子ポリペプチド及びｖ因子ポリペプチドを含む薬学的組成物
US20260007727A1 (en) Drug that promotes hemostasis
JP2005510513A (ja) Ｖｉｉ因子ポリペプチドおよびｔａｆｉポリペプチドを含む薬学的組成物
JP2005510514A (ja) Ｖｉｉ因子ポリペプチド及びｐａｉ−１ポリペプチドを含む薬学的組成物
JP2005511600A (ja) Ｖｉｉ因子ポリペプチドおよびトロンボモジュリンポリペプチドを含む薬学的組成物
HK1188391A (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
HK1188391B (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment